Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):660-666.
doi: 10.21037/tcr-24-1633. Epub 2025 Feb 26.

The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients-a commentary

Saqib Raza Khan  1   2 , Saurav Verma  1   2 , Daniel Breadner  1   2 , Jacques Raphael  1   2   3
Affiliations
Editorial

The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients-a commentary

Saqib Raza Khan et al. Transl Cancer Res. .
No abstract available

Keywords: Lung cancer; TROP2; biomarker; immunotherapy; resistance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1633/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol 2024;42:e23-43. 10.1200/JCO.23.02746 - DOI - PubMed
    1. Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2024;22:249-74. 10.6004/jnccn.2204.0023 - DOI - PubMed
    1. Belaroussi Y, Bouteiller F, Bellera C, et al. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep 2023;13:9584. 10.1038/s41598-023-36623-1 - DOI - PMC - PubMed
    1. Simeone JC, Nordstrom BL, Patel K, et al. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol 2019;15:3491-502. 10.2217/fon-2019-0348 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol 2021;39:2339-49. 10.1200/JCO.21.00174 - DOI - PMC - PubMed

LinkOut - more resources